{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003949","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.014030+00:00","generated_at":"2026-06-07T02:07:28.881964+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Veracyte acquires C2i Genomics for $70M in stock; reports preliminary 2023 revenue up 21%","bullets":["Q4 2023 revenue $95-96M (+18-20% YoY); full-year revenue $358-359M (+21%).","Total test volume ~34,000 in Q4 (+21%), ~127,000 full-year (+24%).","2024 revenue guidance 10-12% growth ($394-402M); cash >$215M at year-end.","Acquires C2i Genomics for $70M in Veracyte shares at close plus up to $25M milestone; expected close Q1 2024.","First MRD test in muscle-invasive bladder cancer, leveraging urology commercial channel."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003949","json":"https://secwatch.observer/filing/0001193125-24-003949.json","markdown":"https://secwatch.observer/filing/0001193125-24-003949.md","text":"https://secwatch.observer/filing/0001193125-24-003949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/0001193125-24-003949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/d543036d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:07:28.881964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19bc60f0c935bc0b3778a9ee1494f8e61f08e0e4","claim":"VERACYTE, INC. reported the full year ended December 31, 2023 results: revenue between $358.0 million and $359.0 million.","evidence_excerpt":"For the full year ended December 31, 2023, as compared to the same period of 2022, Veracyte expects to report: • Revenue of between $358 million and $359 million, an increase of 21%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/0001193125-24-003949-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"between $358.0 million and $359.0 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"2c6dc5f759d575baf032ea4342e9a0340c2f4ee3","claim":"VERACYTE, INC. reported the fourth quarter ended December 31, 2023 results: revenue between $95.0 million and $96.0 million.","evidence_excerpt":"For the fourth quarter ended December 31, 2023, as compared to the same period of 2022, Veracyte expects to report: • Revenue of between $95 million and $96 million, an increase of between 18% and 20%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/0001193125-24-003949-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"between $95.0 million and $96.0 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"9ab05452925d024adc318684c9110171ca1846b8","claim":"VERACYTE, INC. reported full year 2024 results: revenue between $394 million and $402 million. Guidance initiated.","evidence_excerpt":"Veracyte is initiating 2024 testing and product revenue guidance of 13% to 15% growth, partially offset by declining biopharma and other revenue, resulting in total company revenue growth of 10% to 12%, or $394 million to $402 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1384101/000119312524003949/0001193125-24-003949-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"between $394 million and $402 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}